SciSparc & Clearmind Patent for Depression Treatment
Ticker: SPRC · Form: 6-K · Filed: Nov 20, 2025 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Nov 20, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: patent, collaboration, pharmaceuticals, mental-health
TL;DR
SciSparc's Neurothera Labs and Clearmind Medicine filed an Israeli patent for a new depression drug.
AI Summary
On November 20, 2025, SciSparc Ltd. announced that its subsidiary, Neurothera Labs, filed an Israeli patent application in collaboration with Clearmind Medicine. This patent is for a novel non-hallucinogenic neuroplastogen treatment aimed at addressing depression.
Why It Matters
This patent filing could lead to a new, non-hallucinogenic treatment for depression, potentially offering a significant advancement in mental health therapeutics.
Risk Assessment
Risk Level: medium — The filing is a patent application, which is an early stage of development and does not guarantee commercial success or regulatory approval.
Key Players & Entities
- SciSparc Ltd. (company) — Filer of the report
- Neurothera Labs (company) — Subsidiary of SciSparc Ltd.
- Clearmind Medicine (company) — Collaborator on patent application
- November 20, 2025 (date) — Date of press release and patent filing announcement
FAQ
What is the specific nature of the novel non-hallucinogenic neuroplastogen treatment?
The filing describes it as a novel non-hallucinogenic neuroplastogen treatment for depression, but specific details of the compound or mechanism are not provided in this 6-K summary.
What is the current status of the patent application?
The patent application was filed in Israel on November 20, 2025.
What is the relationship between SciSparc Ltd. and Neurothera Labs?
Neurothera Labs is a subsidiary of SciSparc Ltd.
What is the intended therapeutic area for this new treatment?
The intended therapeutic area is depression.
Has this treatment been approved by any regulatory bodies?
No, this is a patent application filing, and there is no indication of regulatory approval in the provided text.
Filing Stats: 324 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2025-11-20 08:30:27
Filing Documents
- ea0266570-6k_scisparc.htm (6-K) — 13KB
- ea026657001ex99-1_scisparc.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 12KB
- 0001213900-25-112861.txt ( ) — 41KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: November 20, 2025 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3